SPEAKER_00: 0:00

Welcome to the Health Pulse, your go-to source for quick, actionable insights on health, wellness, and diagnostics. Whether you're looking to optimize your well-being or stay informed about the latest in-medical testing, we've got you covered. Join us as we break down key health topics in just minutes. Let's dive in.

SPEAKER_01: 0:25

Welcome back to the deep dive. We are uh ripping the cover off a central mystery in cardiology today. Why do some people develop severe heart disease and even suffer heart attacks despite having cholesterol reports that their doctor calls normal?

SPEAKER_02: 0:41

It's a huge question. And one that causes a lot of confusion.

SPEAKER_01: 0:44

Yeah, the standard lipid panel, you know, the one everyone gets, it seems to have this massive blind spot.

SPEAKER_02: 0:50

It really does.

SPEAKER_01: 0:51

And if you have underlying metabolic issues, that blind spot could be hiding, well, a ticking cardiovascular clock.

SPEAKER_02: 0:58

That's precisely it.

SPEAKER_01: 0:59

So today we're diving into the central idea that proves, maybe once and for all, that not all LDL cholesterol is created equal.

SPEAKER_02: 1:07

Aaron Powell That's absolutely right. Our mission today really is to move the conversation past just looking at LDLC.

SPEAKER_01: 1:14

That single number.

SPEAKER_02: 1:15

Yeah, that single number which measures the total mass of cholesterol being transported. We need to zero in on the actual particles.

SPEAKER_01: 1:21

Okay.

SPEAKER_02: 1:21

Specifically their size, their number, and their density. These are the delivery vehicles we need to understand.

SPEAKER_01: 1:27

And introduce the main player.

SPEAKER_02: 1:28

Exactly. We need to introduce you to the most potent, arguably the most dangerous subtype, small dense LDL or SDLDL.

SPEAKER_01: 1:37

Okay, let's unpack this because this really does change the game, doesn't it?

SPEAKER_02: 1:41

Completely.

SPEAKER_01: 1:41

For decades, the mantra has basically been if your LDLC is low, you're safe. But what you're saying is LDLC only measures the cargo, the amount of cholesterol.

SPEAKER_02: 1:51

Just the amount.

SPEAKER_01: 1:52

It tells us nothing about the trucks carrying it. Are they big, easy to manage, 18-wheelers, or or like a swarm of thousands of tiny, aggressive drones?

SPEAKER_02: 2:01

Trevor Burrus, Jr.: That analogy perfectly captures the distinction. It's so critical because two people can walk out of a lab with the exact same LDLC number, say 100.

SPEAKER_01: 2:10

And they're told their risk is identical.

SPEAKER_02: 2:11

Aaron Powell Exactly. They walk away thinking they're in the same boat.

SPEAKER_01: 2:14

Aaron Powell But the reality could be night and day different.

SPEAKER_02: 2:16

Aaron Powell Precisely. Individual A might have maybe a thousand large, harmless, buoyant particles carrying that 100 milligrams of cholesterol. These are pretty easy for the body to handle. Okay. But individual B, well, they might need 2,500 of those tiny dense particles to carry the exact same 100 milligrams of cholesterol mass.

SPEAKER_01: 2:35

Wow, more than double the particles.

SPEAKER_02: 2:37

Aaron Powell Right. And it's the particle number, not just the cholesterol mass inside them that truly drives the risk.

SPEAKER_01: 2:42

Aaron Powell Because the standard LDLC testing misses particle number and size completely.

SPEAKER_02: 2:46

Aaron Powell It does. So two people with the same LDLC score can have, I mean, just drastically different levels of cardiovascular risk. Trevor Burrus, Jr.

SPEAKER_01: 2:54

So let's focus on the real culprit then, SDLDL. You said they're characterized by their small size and high density. Why is that small size such a liability when it comes to, you know, arterial damage?

SPEAKER_02: 3:06

Aaron Powell Well, the key features of SDLDL are exactly what make them fundamentally more anthrogenic. That just means more likely to cause plaque in the arteries. More dangerous. Yes. First, their smaller diameter is critical. Think of the inner lining of your arteries, the endothelium, like a protective barrier, almost like a sieve.

SPEAKER_01: 3:23

Okay.

SPEAKER_02: 3:24

The large fluffy LDL particles. They're generally too big to squeeze through easily.

SPEAKER_01: 3:28

They sort of bounce off.

SPEAKER_02: 3:29

Exactly. But the small diameter of SDLDL allows them to penetrate that arterial wall much more easily. They slip into what's called the sub-endothelial space.

SPEAKER_01: 3:40

Aaron Powell So they get trapped behind the barrier.

SPEAKER_02: 3:42

They get trapped, accumulate, and start building up the foundation for plaque. That's step one.

SPEAKER_01: 3:47

Aaron Powell And the second characteristic you mentioned, higher density, means they're carrying less actual cholesterol per particle, right?

SPEAKER_02: 3:53

Yes, that's right. They're denser because they're relatively depleted of triglycerides and cholesterol esters compared to the larger ones. They're like tiny hard packages.

SPEAKER_01: 4:03

Though you need more of them.

SPEAKER_02: 4:04

You need many more of them. To move the same amount of cholesterol, your body has to produce and release a much greater number of these small dense particles.

SPEAKER_01: 4:14

And that explains why APOB testing is so important.

SPEAKER_02: 4:17

Precisely. APOLIPO protein B, or APOB, measures the total count of these potentially plaque-causing particles. It's a far, far superior risk predictor than LDLC.

SPEAKER_01: 4:27

Aaron Powell Because more particles means more traffic trying to get through that barrier.

SPEAKER_02: 4:32

Exactly. More chances for things to go wrong.

SPEAKER_01: 4:34

Aaron Powell Okay, here's where it gets really interesting. Once these tiny particles actually penetrate the artery wall, what happens next? Let's get into the specific mechanisms you mentioned for that turn this particle size into hard, dangerous plaque.

SPEAKER_02: 4:49

Aaron Powell Right. So that initial step, the enhanced arterial penetration, that just sets the stage. Once they're trapped in that intimal space, they're exposed to a pretty hostile environment.

SPEAKER_01: 4:58

Aaron Powell And I understand step two involves oxidation. SDLDL seems, I don't know, structurally prone to damage.

SPEAKER_02: 5:04

Aaron Powell It is. It's far more susceptible to modification. Inside the artery wall, these SDLDL particles are easily attacked by free radicals. They undergo oxidative modification.

SPEAKER_01: 5:14

Aaron Powell And when SDLDL gets oxidized, it produces OxLDL.

SPEAKER_02: 5:19

Oxidized LDL or OXLDL, yes. And this stuff is highly inflammatory. It's really a destructive form of cholesterol that the immune system sees as basically an invading enemy.

SPEAKER_01: 5:28

So the immune system kicks in, tries to clean up this perceived threat.

SPEAKER_02: 5:32

Aaron Powell Right. And that aggressive immune response is actually what creates the plaque itself. Immune cells called macrophages. They're like the cleanup crew. They engulf the Ox LDL, but they can't really process it effectively. They just get stuffed full and turn into what we call foam cells.

SPEAKER_00: 5:46

Foam cells, okay.

SPEAKER_02: 5:47

And these foam cells aggregate, they clump together, forming the fatty streaks you hear about, and eventually the fibrous plaques that characterize heart disease.

SPEAKER_01: 5:56

Okay, so penetration, then oxidation leading to foam cells. What's the third mechanism? It's about exposure time. If these particles are so bad, the longer they're around, the worse it is.

SPEAKER_02: 6:06

Absolutely. The third key mechanism is their longer circulation time. They just stick around longer.

SPEAKER_01: 6:11

Why is that?

SPEAKER_02: 6:12

The metabolic machinery in the liver, which is supposed to clear out old or damaged LDL from the blood, it's just less efficient at recognizing and removing these SDLDL particles. They do. They persist longer in the bloodstream compared to their larger cousins. This increases the total exposure time for your artery walls.

SPEAKER_01: 6:30

Aaron Powell Which means more opportunities to slip in and get oxidized.

SPEAKER_02: 6:34

Exactly. Many more opportunities for vessel penetration and that dangerous oxidation process.

SPEAKER_01: 6:39

Okay, so they slip in easily, get damaged almost immediately, and they stay in circulation longer. Sounds like a perfect storm for chronic inflammation.

SPEAKER_02: 6:47

Aaron Powell And that leads directly into the fourth mechanism, the pro-inflammatory effects and the structural damage they cause. Right. Once oxidized, SDLDL is a powerful trigger. It ramps up immune cell activation, contributes to endothelial dysfunction, meaning the artery lining stops working properly.

SPEAKER_01: 7:05

Aaron Powell Which makes things even worse.

SPEAKER_02: 7:06

Aaron Powell It does. And importantly, it promotes the proliferation, the growth of smooth muscle cells within the artery wall. This stiffens the artery, thickens it, and ultimately makes the plaque unstable and more prone to rupture.

SPEAKER_01: 7:20

Aaron Powell, which is, of course, what causes heart attacks and strokes.

SPEAKER_02: 7:23

That's the critical event, yes.

SPEAKER_01: 7:24

Aaron Powell So taken together, these four properties easy penetration, easy oxidation, long circulation, and inflammation, explain why just focusing on LDLC is, well, potentially dangerous.

SPEAKER_02: 7:35

It can be dangerously misleading.

SPEAKER_01: 7:37

SDLDL seems perfectly designed to start and progress the blockage process, even if your total cholesterol mass looks fine on paper.

SPEAKER_02: 7:44

This naturally raises an important question. If SDLDL is this primary hidden risk factor and the total cholesterol number can be misleading, what actually causes the elevation of these specific tiny particles?

SPEAKER_01: 7:59

Yeah, because it sounds like we aren't just talking about, you know, eating too much dietary fat anymore.

SPEAKER_02: 8:03

We're certainly not. The data, it's pretty unequivocal now. Elevated SDLDL isn't just an isolated plumbing problem in your arteries.

SPEAKER_01: 8:11

It's a symptom.

SPEAKER_02: 8:11

It's a profound reflection of underlying metabolic failure. The core cause, in most cases, is insulin resistance and the cluster of issues known as metabolic syndrome.

SPEAKER_01: 8:22

Okay, that link seems fundamental.

SPEAKER_02: 8:24

It is. When your body becomes insulin resistant, its ability to manage blood sugar is compromised. This metabolic state dramatically alters lipid metabolism, how your body handles fats.

SPEAKER_00: 8:34

How so?

SPEAKER_02: 8:35

Specifically, insulin resistance leads to an increased production of triglyceride-rich lipoproteins, VLDLs mostly.

SPEAKER_01: 8:41

Which are basically fat carriers, right?

SPEAKER_02: 8:43

Exactly. And when these triglyceride-rich particles interact with the larger, buoyant LDL particles in your blood, an enzyme called CETP cholesterol ester transfer protein gets hyperactive.

SPEAKER_01: 8:56

What does CETP do?

SPEAKER_02: 8:57

It essentially swaps components between particles. It strips cholesterol esters out of the normal LDL and replaces them with triglycerides from the V LDL.

SPEAKER_01: 9:06

So the LDL gets loaded up with triglycerides.

SPEAKER_02: 9:09

Right. This creates a new triglyceride-rich LDL particle. Then other enzymes process this further, stripping away those newly acquired triglycerides and what's left behind.

SPEAKER_01: 9:18

The small, dense LDL.

SPEAKER_02: 9:20

The small, dense, highly dangerous STLDL. It's literally a conversion process, driven entirely by your underlying metabolic state, particularly how you handle carbs and sugar.

SPEAKER_01: 9:29

So high levels of SDLDL are really a symptom of the insulin resistance, not the primary illness itself. And this is heavily influenced by diet you mentioned.

SPEAKER_02: 9:37

Oh, absolutely. The sources strongly connect high carbohydrate and especially high sugar diets to this whole problem. These diets are known to dramatically increase triglycerides. That's the fuel for the conversion process we just discussed. And they also tend to lower HDL cholesterol, the good cholesterol. Both factors strongly favor the shift toward SDLDL dominance.

SPEAKER_01: 9:57

So it's a cascading metabolic failure, often driven by too much glucose and fructose.

SPEAKER_02: 10:02

Largely, yes. From processed foods, sugary drinks, excessive carbs relative to your metabolic tolerance.

SPEAKER_01: 10:10

And beyond diet, there are physical factors, like obesity, specifically belly fat.

SPEAKER_02: 10:15

Yes. Excess abdominal or visceral fat, the fat stored around your organs, is strongly associated with SDLDL dominance.

SPEAKER_01: 10:21

Why that fat in particular?

SPEAKER_02: 10:23

Aaron Ross Powell Because visceral fat is highly metabolically active. It churns out inflammatory signals and hormones that fuel chronic inflammation and worsen that whole cycle of insulin resistance.

SPEAKER_01: 10:32

Makes sense. And lifestyle activity levels.

SPEAKER_02: 10:34

Of course. Low physical activity just makes all these factors worse. It promotes insulin resistance, raises triglycerides, and basically maximizes the SDLDL conversion rate.

SPEAKER_01: 10:43

So lifestyle is the major lever here.

SPEAKER_02: 10:46

It really is. Though we should mention genetics can play a role too. Certain genetic variations, like ApoE polymorphisms, can make some individuals a bit more predisposed to this SDLDL pattern, even with good habits. But for most, it's lifestyle driven.

SPEAKER_01: 11:03

This shift in focus feels critical. We're moving from, you know, just blaming butter to really examining sugar metabolism and sedentary habits.

SPEAKER_02: 11:12

Aaron Powell That's a good way to put it.

SPEAKER_01: 11:13

And the evidence confirming that SDLDL is a better predictor of heart risk is substantial, right? That's what justifies this deep dive.

SPEAKER_02: 11:21

Aaron Powell Oh, it's beyond debate now in the research community. Major prospective studies like the Quebec cardiovascular study and the very long-running Framingham offspring study, they confirmed this pattern decades ago.

SPEAKER_01: 11:32

What did they find, essentially?

SPEAKER_02: 11:33

They demonstrated conclusively that individuals with a higher proportion of SDLDL had a significantly increased risk of coronary artery disease. Period.

SPEAKER_01: 11:42

And the really key finding was that this elevated risk remained true even after.

SPEAKER_02: 11:47

Even after they statistically adjusted for total LDLC and even triglyceride levels. That's crucial. It confirms SDLDL is an independent risk factor for coronary heart disease.

SPEAKER_01: 11:58

Meaning it adds risk information above and beyond the standard numbers.

SPEAKER_02: 12:02

Correct. And this risk is especially pronounced in patients already dealing with type 2 diabetes or metabolic syndrome. If you have those conditions, SDLDL is very likely driving your cardiovascular risk.

SPEAKER_01: 12:14

And we can actually see the physical evidence now, can't we? The data connects SDLDL directly to actual plaque formation measured with modern imaging.

SPEAKER_02: 12:23

Exactly. Clinical imaging really reinforces this. Studies using coronary artery calcium scoring, the CAC score, or carotid intima media thickness, CIMT, they show a much stronger correlation between higher SDLDL levels and subclinical atherosclerosis.

SPEAKER_01: 12:37

Which is the actual physical buildup of plaque before symptoms start.

SPEAKER_02: 12:40

Right. A much stronger correlation than standard lipid measures like LDLC show. Basically, the particle size predicts the plaque burden better.

SPEAKER_01: 12:47

Okay, this makes it clear. If a patient has any signs of metabolic syndrome, high blood sugar, belly fat, high triglycerides, low HDL, and they only rely on a standard cholesterol panel, they are potentially missing crucial data.

SPEAKER_02: 13:00

They absolutely are.

SPEAKER_01: 13:01

So since SDLDL is this hidden variable in standard testing, what specialized lab tests are crucial for someone to get a complete cardiovascular risk picture, especially those folks with metabolic issues.

SPEAKER_02: 13:13

We absolutely need to pivot. We need to move from measuring cholesterol mass to measuring particle count and size. Advanced lipid testing is necessary here.

SPEAKER_01: 13:21

Aaron Powell Like what specifically?

SPEAKER_02: 13:23

Look for tests that explicitly provide LDL particle number, usually written as LDLP. That number is often the single most important predictor of risk.

SPEAKER_01: 13:31

More important than LDLC.

SPEAKER_02: 13:32

Often, yes, especially when LDLC and LDLP tell different stories, which happens frequently in insulin resistance. These advanced panels, like NMR lapoprofile or cardio IQ, will also specify the percentage or quantity of SDLDL, letting you know if you have that dangerous pattern of predominantly small particles.

SPEAKER_01: 13:51

Okay, LDLP and SDLDL quantification. What about other markers that tie back to the particle count? You mentioned APO B earlier.

SPEAKER_02: 13:59

APOLIPOProtein B or APOB is non-negotiable in my view. Remember, there's one APOB molecule on every single atherogenic particle, LDL, VLDL remnants, IDL.

SPEAKER_01: 14:11

So it's a direct count of all the bad guys.

SPEAKER_02: 14:14

It's essentially a direct count of all potentially plaque forming particles, including SDLDL. If your APOB is high, you have a high number of these particles and thus a higher risk, almost regardless of what your LDLC value says.

SPEAKER_01: 14:27

If you only remember one number today, maybe make it APOB.

SPEAKER_02: 14:31

It's certainly a top contender for the single best marker.

SPEAKER_01: 14:34

And since we've established this entire problem is so deeply rooted in metabolic health, we have to look at the context of glucose and insulin too, surely.

SPEAKER_02: 14:41

Absolutely. Advanced lipid panels are kind of incomplete without also measuring markers of inflammation like high sensitivity, CRP, HSERP, and crucially your glucose and insulin status.

SPEAKER_01: 14:51

What tests there?

SPEAKER_02: 14:52

Fasting glucose, HBA1C, which shows your average blood sugar over months, and ideally fasting insulin levels. These tell us the severity of your underlying insulin resistance.

SPEAKER_01: 15:02

And that gives you the reason why the SDLDL is high.

SPEAKER_02: 15:05

Exactly. It provides the why. You can't effectively treat the SDLDL particle pattern long term without addressing the root cause, the metabolic dysfunction, the insulin resistance.

SPEAKER_01: 15:16

And the good news maybe is that getting this kind of deep insight is becoming easier. The sources mentioned the growth of services offering these advanced lipid panels and metabolic testing.

SPEAKER_02: 15:25

Yes. Accessibility is improving.

SPEAKER_01: 15:27

Options like at-home specimen collection, I think Quick Lab Mobile was mentioned for Miami, make proactive monitoring more convenient for people who really want to take control.

SPEAKER_02: 15:38

That convenience factor is transformative, I think. Getting this detailed data allows doctors and patients to personalize lifestyle changes and, if necessary, treatments that target the cause of the insulin resistance. Trevor Burrus, Jr.

SPEAKER_01: 15:49

Which then naturally reduces the SDLDL particle count.

SPEAKER_02: 15:52

Right. It's a much more targeted and effective approach than just blindly prescribing a statin sometimes to chase a standard LDL C number that might not even be the main problem for that individual. It doesn't tell the whole story.

SPEAKER_01: 16:03

Aaron Powell So what does this all mean then? Let's try to wrap this up. The key takeaway seems simple, but profound. Small dense LDL is a powerful, often hidden driver of atherosclerosis. It's really not just about the amount of cholesterol you carry, but the nature, the type of the particles carrying it.

SPEAKER_02: 16:23

Aaron Powell Precisely. Size and number matter immensely.

SPEAKER_01: 16:26

And if you have normal cholesterol on a standard test, but you also have underlying issues like insulin resistance, maybe some extra belly fat, prediabetes, or full-blown diabetes.

SPEAKER_02: 16:35

Then SDLDL could absolutely be the reason your actual cardiovascular risk is dangerously elevated, despite that normal report.

SPEAKER_01: 16:42

Identifying this specific particle pattern through tests like LDLP or APOB can literally be the difference between getting a falsely reassuring result and uncovering an urgent but thankfully treatable risk factor.

SPEAKER_02: 16:54

That's well said. And maybe that leads us to a final provocative thought for you, the listener, to consider. Okay. Given that SDLDL elevation is so deeply and intrinsically tied to insulin resistance, metabolic syndrome, and diets high in refined carbohydrates and sugar.

SPEAKER_01: 17:08

The things that fuel that conversion process we talked about.

SPEAKER_02: 17:11

Exactly. Given that link, the traditional decades-long focus almost exclusively on dietary fat as the main villain for heart health well may need significant, perhaps permanent reevaluation. The true heart risk for many people might be less about the fat they eat and much, much more about how their body processes sugars and carbs, because that's what ultimately dictates the size, density, and number of their dangerous LDL particles.

SPEAKER_00: 17:37

Food for thought.com. Stay informed, stay healthy, and we'll catch you in the next episode.